8-KLeadership ChangesRegulation FDExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Oct 27, 2025)

Filed October 27, 2025For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced a change in its Board of Directors composition through an 8-K filing on October 27, 2025. The company has appointed Dr. Euan Ashley as a new director, effective immediately, increasing the Board's size to ten members. Dr. Ashley's appointment is significant as he brings expertise and will serve on the Nominating and Governance Committee and the Technology Committee. This move is part of a broader board expansion strategy previously announced, which includes the appointment of Jacob S. Leach effective January 1, 2026. The appointment of Dr. Ashley is structured with a standard director compensation package, including an initial equity grant of $500,000 in restricted stock units (RSUs) vesting over three years, and eligibility for future annual equity awards. His qualifications are deemed independent, aligning with Nasdaq listing standards. This strategic addition to the board aims to bolster governance and technological oversight, reflecting DexCom's commitment to strong leadership as it continues to grow.

Key Highlights

  • 1DexCom appointed Dr. Euan Ashley to its Board of Directors, effective immediately.
  • 2The Board size was increased to ten directors with Dr. Ashley's appointment.
  • 3Dr. Ashley will serve on the Nominating and Governance Committee and the Technology Committee.
  • 4Kyle Malady will step down from the Nominating Committee but remain Chair of the Technology Committee.
  • 5The Board size will further increase to eleven directors effective January 1, 2026, confirming Jacob S. Leach's previously announced appointment.
  • 6Dr. Ashley received an initial equity grant of $500,000 in RSUs, vesting over three years.
  • 7Dr. Ashley is considered an independent director, meeting Nasdaq listing standards.

Frequently Asked Questions

Dr. Euan Ashley has been appointed as a new director to DexCom's Board. He will serve for a term expiring at the 2026 annual meeting and will be a member of both the Nominating and Governance Committee and the Technology Committee.

Dr. Ashley's appointment initially increased the Board size to ten directors. The filing also notes that the Board size will further increase to eleven directors effective January 1, 2026, to accommodate the previously announced appointment of Jacob S. Leach.

Upon appointment, Dr. Ashley received an initial equity grant of restricted stock units (RSUs) valued at $500,000, which will vest annually over three years. He is also eligible for the standard annual equity grant for non-employee directors, valued at $345,000 for the upcoming year, with vesting conditions tied to continued service.

Yes, the Board determined that Dr. Ashley qualifies as an independent director according to the Securities Act of 1933 and Nasdaq listing standards.